Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature
Leptin and melatonin's effects on OVX rodents' bone metabolism [PMID: 37455920] Laboratory literature summary: Leptin and melatonin's effects on OVX rodents' bone metabolism
Never use peptides that have been left at room temperature for extended periods
The lowest price can help hundreds of millions According to the National Center for Health Statistics, nearly three-quarters of American adults over the age of 20 are overweight or obese, a staggering 246 million Americans
These skin-brightening injections can correct any dark spots or discolouration on the skin
Routine monitoring should include discussing any new or changed symptoms at your regular diabetes or weight management reviews
